References
- Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P. Results of a randomised Phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Ann. Oncol. 23(Suppl. 9), ixe28 (2012).
- ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl. 7), vii92–vii99 (2012).
- Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27(25), 4188–4196 (2009).
- van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 379(9829), 1879–1886 (2012).
- Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J. Clin. Oncol. 25(19), 2755–2763 (2007).
- García-del-Muro X, López-Pousa A, Maurel J et al. Randomized Phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J. Clin. Oncol. 29(18), 2528–2533 (2011).
- Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23(24), 5484–5492 (2005).
- Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin. Cancer Res. 14(20), 6656–6662 (2008).
- Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595–602 (2007).
- Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol. 23(3), 771–776 (2012).
- Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage Phase II clinical trials. Biometrics 51(4), 1372–1383 (1995).
- Saada E, Rahal C, Ray-Coquard I et al. Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: the experience of the French Sarcoma Group (FSG). J. Clin. Oncol. 30(Suppl.), Abstract 10062 (2012).
- Messersmith WA, Jimeno A, Ettinger D et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 63(1), 181–188 (2008).
Websites
- ClinicalTrials.gov. Study of palifosfamidetris in combination with doxorubicin in patients with front-line metastatic soft tissue sarcoma (PICASSO III). http://clinicaltrials.gov/show/NCT01168791
- ClinicalTrials.gov. A trial of TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma. http://clinicaltrials.gov/show/NCT01440088
- ClinicalTrials.gov. Clinical trial of doxorubicin versus trabectedin plus doxorubicin in the first line treatment of patients with advanced non operable and/or metastatic soft tissue sarcomas. http://clinicaltrials.gov/ct2/show/NCT01104298
- ClinicalTrials.gov. A study of the safety and effectiveness of trabetedin versus doxorubicin-based chemotherapy in patients with translocation-related sarcomas (TRS). http://clinicaltrials.gov/ct2/show/NCT00796120
- ClinicalTrials.gov. Doxorubicin hydrochloride or trabectedin in treating patients with previously untreated advanced or metastatic soft tissue sarcoma. http://clinicaltrials.gov/show/NCT01189253
- Institut de Cancérologie Gustave Roussy. Phase II multicentre study to determine the efficacy of doxorubicin in combination with trabectedin (Yondelis®) as a first-line treatment for patients presenting with metastatic leiomyosarcoma (uterine or soft tissue) and/or inoperable relapse (LMS-02). www.igr.fr/index.php?p_m=igrinter&p_a=essai&p_sa=cancer-12
- ClinicalTrials.gov. Localized high-risk soft tissue sarcomas of the extremities and trunk wall in adults: an integrating approach comprising standard vs histotype-tailored neoadjuvant chemotherapy. http://clinicaltrials.gov/show/NCT01710176
- ClinicalTrials.gov. Continuing vs intermittent trabectedin-regimen in patients with advanced soft tissue sarcoma experiencing response or stable disease after the 6th cycle (T-DIS). http://clinicaltrials.gov/ct2/show/NCT01303094
- Agenzia Italiana del Farmaco Front End. Trabectedin in soft tissue sarcomas pretreated with conventional chemotherapy. Evaluation of the ‘tumour microenvironment’. www.agenziafarmaco.gov.it/frontend/cortesia.html
- ClinicalTrials.gov. Therapeutic response of patients with soft tissue sarcoma according to CHOI criteria (ProAcTyon). http://clinicaltrials.gov/ct2/show/NCT01650077
- ClinicalTrials.gov. Combination therapy of gemcitabine and trabectedin in L-sarcomas. http://clinicaltrials.gov/ct2/show/NCT01426633
- ClinicalTrials.gov. A study of trabectedin or dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma. http://clinicaltrials.gov/show/NCT01343277